SOCRATES-REDUCED (Klaar)

A randomized parallel-group, placebo-controlled, multi-center dose finding phase II trial exploring the pharmacodynamic effects, safety and tolerability, and pharmacokinetics of four dose regimens of the oral sGC stimulator BAY 1021189 over 12 weeks in patients with heart failure with reduced ejection fraction (HFrEF) suffering from worsening signs and symptoms of Heart Failure (HF) - SOluble guanylatguanylate Cyclase stimulatoR in heArT failurE patientS with REDUCED EF (SOCRATES-REDUCED)